Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high cmv risk in transplant recipients, established use of immune globulins, clinical effectiveness in prevention, hospital protocol integration, rising organ transplant procedures.

The growth in the forecast period can be attributed to growth in transplant volumes, increasing immunosuppressed populations, expansion of antiviral combination therapies, improved cmv screening, rising specialty pharmacy access. Major trends in the forecast period include rising use in transplant patients, increased demand for cmv prophylaxis, combination therapy with antivirals, hospital based immunoglobulin administration, focus on immunocompromised populations.

The increasing number of transplant procedures is expected to drive the growth of the Cytogam (cytomegalovirus immune globulin intravenous) market in the coming years. Transplant procedures are medical surgeries in which an organ or tissue is transferred from a donor to a recipient to replace a damaged or non-functioning organ. The growth in transplant procedures is supported by factors such as higher organ donation rates, advancements in medical technologies, and improvements in treatment options. Cytogam (cytomegalovirus immune globulin intravenous) is mainly used to prevent or manage cytomegalovirus (CMV) infections in immunocompromised individuals, particularly patients undergoing organ transplantation. For instance, in January 2024, according to the Organ Procurement and Transplantation Network (OPTN), a US-based government agency, a total of 46,632 organ transplants were performed using both living and deceased donors in 2023, representing an 8.7% increase compared with 2022. Therefore, the rising number of transplant procedures is contributing to the growth of the Cytogam (cytomegalovirus immune globulin intravenous) market.

The increasing burden of chronic diseases is also expected to propel the growth of the Cytogam (cytomegalovirus immune globulin intravenous) market going forward. Chronic diseases are long-term health conditions that typically progress slowly and persist for many years. The prevalence of chronic diseases is rising largely due to unhealthy lifestyle patterns, including poor dietary habits and insufficient physical activity. Cytogam (cytomegalovirus immune globulin intravenous) supports chronic disease management by enhancing immune protection against CMV infections in high-risk patients, particularly those with prolonged immunocompromised states. For instance, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research organization, reported that more than half a billion people worldwide were living with diabetes, a figure projected to more than double to 1.3 billion by 2050. As a result, the growing prevalence of chronic diseases is driving the expansion of the Cytogam (cytomegalovirus immune globulin intravenous) market.

Leading companies operating in the Cytogam (cytomegalovirus immune globulin intravenous) market are emphasizing innovative strategies, including manufacturing technology transfer, to strengthen their competitive position. Manufacturing technology transfer involves the systematic transfer of knowledge, processes, and production techniques from one organization or facility to another, ensuring consistent product quality and regulatory compliance. For example, in May 2023, Kamada Ltd., an Israel-based biopharmaceutical company, initiated commercial sales of CYTOGAM in the United States following FDA approval of the manufacturing technology transfer from CSL Behring. CYTOGAM, indicated for the prevention of CMV disease in transplant patients, is the only IgG product approved by the FDA for this indication. Kamada’s manufacturing facility in Beit Kama, Israel, now produces CYTOGAM, with availability in Canada anticipated later in the year.

Major companies operating in the cytogam (cytomegalovirus immune globulin intravenous) market are CSL Behring.

North America was the largest region in the cytogam (cytomegalovirus immune globulin intravenous) market in 2025. The regions covered in the cytogam (cytomegalovirus immune globulin intravenous) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cytogam (cytomegalovirus immune globulin intravenous) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the cytogam market by increasing costs related to plasma collection, fractionation equipment, and cold chain transportation. These effects are most visible in regions dependent on imported plasma derived products such as Asia Pacific and parts of Europe. Hospital pharmacies face moderate pricing pressure due to higher acquisition costs. Supply chain complexity has increased due to customs and compliance requirements. On the positive side, tariffs are encouraging domestic plasma processing and strengthening regional immunoglobulin supply resilience.

The cytogam (cytomegalovirus immune globulin intravenous) market research report is one of a series of new reports that provides cytogam (cytomegalovirus immune globulin intravenous) market statistics, including cytogam (cytomegalovirus immune globulin intravenous) industry global market size, regional shares, competitors with a cytogam (cytomegalovirus immune globulin intravenous) market share, detailed cytogam (cytomegalovirus immune globulin intravenous) market segments, market trends and opportunities, and any further data you may need to thrive in the cytogam (cytomegalovirus immune globulin intravenous) industry. This cytogam (cytomegalovirus immune globulin intravenous) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cytogam (Cytomegalovirus Immune Globulin Intravenous) is an intravenous therapy used for the prevention and treatment of Cytomegalovirus (CMV) infections in immunocompromised individuals, including organ transplant recipients. It contains antibodies obtained from human plasma that assist in combating the CMV virus. Cytogam is commonly administered to prevent CMV reactivation or new infection and is often used alongside antiviral medications. This therapy helps lower the risk of CMV-related complications in high-risk patients.

The primary dosage forms of Cytogam (cytomegalovirus immune globulin intravenous) include intravenous (IV) injection and other available formulations, if applicable. Intravenous injection involves delivering Cytogam directly into the bloodstream through a vein. Its clinical indications include the prevention of cytomegalovirus disease in transplant recipients, prophylactic use in solid organ transplant patients, prophylaxis in hematopoietic stem cell transplant patients, and use in pregnant women with primary CMV infection. The treatment is suitable for both adult and pediatric patient populations, and it is distributed through hospital pharmacies, outpatient clinics, and specialty pharmacies.

The cytogam (cytomegalovirus immune globulin intravenous) market consists of sales of Cytogam (Cytomegalovirus Immune Globulin Intravenous) 500 mg/10 mL and Cytogam (Cytomegalovirus Immune Globulin Intravenous) 1000 mg/20 mL. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.